FindTrial
Sign In

Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Status
APPROVED_FOR_MARKETING
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04914247
Enrollment
Unknown
Registered
2021-06-04
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-healing Wound, Thromboangiitis Obliterans

Brief summary

The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the treatment of participant with non-healing wound, buerger's disease.

Interventions

DRUGSelexipag

Sponsors

Actelion
Lead SponsorINDUSTRY

Eligibility

Contacts

STUDY_DIRECTORActelion Clinical Trial

Actelion

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026